Psychiatr. praxi. 2020;21(1):47-52 | DOI: 10.36290/psy.2020.009

Atomoxetine

MUDr. Daniela Zmeškalová, Ph.D.
Dětská a dorostová psychiatrická ambulance, Psychiatrická klinika, LF UP v Olomouci a FN Olomouc

Atomoxetine is a selective norepinephrine-reuptake inhibitor indicated for the management of ADHD (F90.0) in children over six years of age, adolescents and adults. There is positive evidence for effectiveness of atomoxetine on core ADHD symptomatology and various comorbid conditions and quality of life. Commonly reported side effects, especially in the beginning of treatment, include headache, stomachache and decreased appetite. Atomoxetine can affect heart rate and blood pressure; cardiovascular status should be regularly monitored. The persistence of the therapeutic effect of atomoxetine through 24 hours enables once-daily dosing and thus can maintain efficacy in treating the symptoms of ADHD beyond the initial hours of the day spent in school, such as during afternoon study time, leisure activities or preparing for bed.

Keywords: atomoxetine, hyperkinetic disorder, ADHD.

Published: May 15, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zmeškalová D. Atomoxetine. Psychiatr. praxi. 2020;21(1):47-52. doi: 10.36290/psy.2020.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27(5): 699-711. Go to original source... Go to PubMed...
    2. Witcher JW, Long A, Smith B et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003; 13: 53-63. Go to original source...
    3. Farid NA, Bergstrom RF, Ziege EA et al. Single‑dose and steady‑state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol. 1985; 25: 296-301. Go to original source...
    4. Sauer JM, Ring BJ, Witcher JW. Clinical Pharmacokinetics of Atomoxetine. Clin Pharmacokinet, 2005; 44(6): 571-590. Go to original source... Go to PubMed...
    5. Strattera, atomoxetine (summary of product characteristics). [cited 2020 Feb 1]. Available from https://www.medicines.org.uk/emc/medicine/14482.
    6. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51(01/02): 9-62. Go to original source... Go to PubMed...
    7. Ptáček R, Goetz M. Hyperkinetické poruchy (ADHD) u dětí in Doporučené postupy psychiatrické péče 2018. [cited 2020 Feb 1]. https://postupy‑pece.psychiatrie.cz/specialni‑psychiatrie/f9-adhd/adhd‑deti.
    8. Prasad S, Steer C. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention‑deficit/hyperactivity disorder. Pediatr Drugs, 2008; 10: 39-47. Go to original source...
    9. Ptáček R, Goetz M, Mohr P. Hyperkinetická porucha u dospělých in Doporučené postupy psychiatrické péče 2018. [cited 2020 Feb 1]. Available from https://postupy‑pece.psychiatrie.cz/specialni‑psychiatrie/f9-adhd/adhd‑dospeli.
    10. Schottenfeld RS, Chawarski MC, Sofuoglu M, et al. Atomoxetine for amphetamine‑type stimulant dependence during buprenorphine treatment: A randomized controlled trial. Drug Alcohol Depend. 2018; 186: 130-137. Go to original source...
    11. Dadashova R, Silverstone PH. Off‑label use of atomoxetine in adults: is it safe? Ment Illn. 2012; 4(2): e19. Go to original source... Go to PubMed...
    12. Wehmeier PM, Schacht A, Wolff C, et al. Neuropsychological outcomes across the day in children with attention‑deficit/hyperactivity disorder treated with atomoxetine: results from a placebo controlled study using a computer‑based continuous performance test combined with an infra‑red motion‑tracking device. J Child Adolesc Psychopharmacol. 2011; 21(5): 433-444. Go to original source...
    13. Savill NC, Buitelaar JK, Anand E, et al. The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention‑Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research. CNS Drugs. 2015; 29(2): 131-151. Go to original source...
    14. Clemow DB, Bushe C, Mancini M, et al. A review of the efficacy of atomoxetine in the treatment of attention‑deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat. 2017; 13: 357-371 Go to original source...
    15. Asherson P, Bushe C, Saylor K, et al. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo‑controlled trials. J Psychopharmacol. 2014; 28(9): 837-846. Go to original source... Go to PubMed...
    16. Walker DJ, Mason O, Clemow DB, et al. Atomoxetine treatment in adults with attention‑deficit/hyperactivity disorder. Postgrad Med, 2015; 127(7): 686-701. Go to original source... Go to PubMed...
    17. Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2015; 12: 27-39. Go to original source...
    18. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention‑deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta‑analysis. Lancet Psychiatry. 2018; 5(9): 727-738. Go to original source...
    19. Liang EF, Lim SZ, Tam WW, et al. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention‑Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta‑Analysis, and Meta‑Regression. Int J Environ Res Public Health. 2018; 15(8): E1789 Go to original source... Go to PubMed...
    20. Houghton R, de Vries F, Loss G. Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder. CNS Drugs. 2020; 34(1): 93-101. Go to original source...
    21. Williams AE, Giust JM, Kronenberger WG, et al. Epilepsy and attention‑deficit hyperactivity disorder: links, risks, and challenges. Neuropsychiatr Dis Treat. 2016; 12: 287-296. Go to original source...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.